Right. So, Driehaus Capital Management – bless their ambitious hearts – just dropped $15.52 million on Xenon Pharmaceuticals. 369,577 shares. A perfectly reasonable sum to wager on a biotech, wouldn’t you say? Honestly, I’ve seen less reckless bets at a charity auction. I’m watching, naturally. Always watching. It’s not that I want things to go south, it’s just… I’ve developed a certain fondness for the controlled chaos of a well-timed correction.
What Happened (Or, What They’re Hoping Happened)
The filing shows Driehaus increased its stake in Xenon during the fourth quarter. A tidy little addition to their portfolio. It’s now 1.4% of their 13F reportable assets. Which, let’s be honest, is a commitment. Like, “I’m seeing this through, even if it involves late-night stress-eating and questionable life choices” kind of commitment. The total position value bumped up to $36.03 million. Numbers. They’re mesmerizing, aren’t they? Especially when they represent someone else’s money.
The Rest of the Portfolio (And Who Else is Playing This Game)
- Here’s the breakdown of their top holdings, for those of you who like a bit of voyeurism:
- NYSE:TSM: $657.49 million (4.5% of AUM)
- NASDAQ:CRNX: $297.35 million (2.0% of AUM)
- NASDAQ: PRAX: $275.01 million (1.9% of AUM)
- NASDAQ:GH: $218.91 million (1.5% of AUM)
- NASDAQ:XENE: $203.42 million (1.4% of AUM)
- Xenon’s shares, as of Friday, were trading at $58.33. Up 66% over the year. Which, in biotech terms, is practically a lifetime. The S&P 500? A mere 19%. Pathetic, really.
Xenon: A Quick Profile (For Those Who Aren’t Fluent in Biotech Jargon)
| Metric | Value |
|---|---|
| Price (as of Friday) | $58.33 |
| Market Capitalization | $4.9 billion |
| Revenue (TTM) | $7.50 million |
| Net Income (TTM) | ($345.91 million) |
So, Xenon develops stuff for neurological disorders. Epilepsy, mostly. They’re all about potassium and sodium channel modulators – which sounds terrifyingly futuristic, doesn’t it? They’re based in Canada, which… honestly, I just find charming. It’s a clinical-stage company, which means they’re still spending money faster than they’re making it. A familiar story.
What This Means (Or, What I’m Telling Myself to Justify Watching This Train)
Right, the big news: azetukalner. Their lead drug candidate. Phase 3 data for focal onset seizures came back strong. Seizures dropped by a median 53.2% in the high-dose group. Compared to 10.4% for placebo. Not bad, not bad at all. More than half of the patients saw at least a 50% reduction. And they’re planning to file for U.S. regulatory approval. Soon.
They also raised $747.5 million in a public offering. Which, let’s be real, is a lot of money. Enough to fund commercialization and expand the pipeline. The market reacted, predictably. Shares surged 30% after the results and financing. It’s all very… exhilarating.
Within Driehaus’ portfolio, it fits nicely alongside other neuroscience bets like Crinetics and Praxis. But Xenon? Xenon might be the one to watch. It’s got that certain… spark. That dangerous, potentially ruinous spark. And honestly? I’m here for it. I’m always here for the chaos.
Read More
- Building 3D Worlds from Words: Is Reinforcement Learning the Key?
- The Best Directors of 2025
- 2025 Crypto Wallets: Secure, Smart, and Surprisingly Simple!
- 20 Best TV Shows Featuring All-White Casts You Should See
- Mel Gibson, 69, and Rosalind Ross, 35, Call It Quits After Nearly a Decade: “It’s Sad To End This Chapter in our Lives”
- Umamusume: Gold Ship build guide
- Uncovering Hidden Signals in Finance with AI
- TV Shows That Race-Bent Villains and Confused Everyone
- Gold Rate Forecast
- Actors Who Refused Autographs After Becoming “Too Famous”
2026-03-13 16:54